IRADIMED reports record Q2 revenue of $16.1M, raises FY2023 guidance

IRADIMED CORP

2023-Q2 EPS reported $0.60 revenue$31,605,480

Q2 revenue $16.1M (+25% YoY); GAAP diluted EPS $0.33 vs $0.26; non-GAAP EPS $0.36 vs $0.26.
Operating income $5.0M, up 19% YoY; 8th consecutive record revenue quarter.
Monitoring devices revenue grew 25% YoY to $6.1M; IV pump systems up 17% to $4.5M.
FY2023 guidance raised: rev $64.5-$65.5M, GAAP EPS $1.25-$1.28, non-GAAP EPS $1.37-$1.40.
Q3 2023 guidance: rev $16.1-$16.3M, GAAP EPS $0.33-$0.35, non-GAAP EPS $0.36-$0.38.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

IRADIMED CORP reported second quarter ended June 30, 2023 results: revenue $16.1 million, net income $4.2 million, EPS $0.33 per diluted share. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $16.1 million
Net income: $4.2 million
EPS: $0.33 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

For the second quarter ended June 30, 2023, the Company reported over 25% year-over-year revenue growth to $16.1 million compared to $12.7 million for the second quarter of 2022. Net income was $4.2 million, or $0.33 per diluted share, compared to $3.2 million, or $0.26 per diluted share for the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-013067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.